Author: admin

Posted on

EA2183 – Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

NCT#:NCT04248452
NCT QR Code
Title:Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Protocol:EA2183
Cancer Type: Esophageal/Gastric
Study Sponsor: NCI / ECOG-ACRIN
Brief Summary:  This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Study Type: Interventional
Date Opened at SVH:  2-Sep-2021
Recruitment Status:  Recruiting
Study Population:   
Eligibility Criteria: See Schema
Principal Investigator:  Hong Zhao, MD, Oncology, Salinas Valley Health Cancer Care, (831) 755-1701
Participating Institution:  Salinas Valley Health
Salinas Valley Health Clinical Research Program:  Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager,  [email protected]
Link to ClinicalTrials.gov:  https://clinicaltrials.gov/ct2/show/record/NCT04248452?term=EA2183&draw=2&rank=1
Physician Fact Sheet:EA2183
Schema

Posted on

EA5182 – Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

NCT#:NCT04181060
NCT QR Code
Title:Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Protocol:EA5182
Cancer Type: Lung
Study Sponsor: NCI / ECOG-ACRIN
Brief Summary:  This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Study Type: Interventional
Date Opened at SVH:  2-Sep-2021
Recruitment Status:  Recruiting
Study Population:   
Eligibility Criteria: See SCHEMA
Principal Investigator:  Hong Zhao, MD, Oncology, SVMC Cancer Care, (831) 755-1701
Participating Institution:  Salinas Valley Memorial Healthcare System & Salinas Valley Medical Clinics & Salinas Valley Memorial Hospital
SVH Clinical Research Program:  Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager,  [email protected]
Link to ClinicalTrials.gov:  https://clinicaltrials.gov/ct2/show/record/NCT04181060?term=EA5182&draw=2&rank=1
Physician Fact Sheet:EA5182
SCHEMA
Posted on

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT#:NCT02488967
NCT QR Code
Title:Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Protocol:NRG-BR003
Cancer Type: Breast
Study Sponsor: NCI / ECOG-ACRIN
Brief Summary:  This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
Study Type: Interventional
Date Opened at SVMHS:  28-Jan-2016
Recruitment Status:  Closed
Study Population:   
Eligibility Criteria: The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination
Principal Investigator:  Hong Zhao, MD, Oncology, SVMC Cancer Care, (831) 755-1701
Participating Institution:  Salinas Valley Memorial Healthcare System & Salinas Valley Medical Clinics & Salinas Valley Memorial Hospital
SVMHS Clinical Research Program:  Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected]
Link to ClinicalTrials.gov:  https://clinicaltrials.gov/ct2/show/record/NCT02488967?term=NRG-BR003&draw=2&rank=1